- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
ECCMID late-breaking sessions to focus on colistin resistance and migrant health
29 March 2016 • Author: Victoria White
Amongst the plethora of entries, two special tracks were opened up for topics that have not only high scientific importance, but also relevance on a global scale: colistin resistance and migrant health. A total of 340 late-breaker abstracts have been submitted, 25 of which are related to refugee health, 44 to colistin resistance, and 271 on other topics. The ECCMID Programme Committee selected the most interesting and scientifically significant late-breaking abstracts to be presented to the global infectious disease and microbiology community in three dedicated oral sessions and additional poster presentations.
With thousands of people currently migrating to other territories, there is a challenge for public health systems in transition and host countries to keep up with any new or emerging infections. Having eradicated a number of infectious diseases such as diphtheria and polio, over the past centuries, Europe is being threatened with the reemergence of several infections, forcing clinicians and public health specialists to develop strategies for the screening, the prevention, and the treatment of these diseases.
Emerging colistin resistance
Separately, the second focus of the late-breaking abstracts is on emerging colistin resistance. Reports about the spread of plasmid-borne resistance to this last-resort antibiotic have come from China, Canada, the UK and most countries in continental Europe. These new report have revealed how easily resistant bacterial strains can spread and the latent threat they pose to current and future patient care.
In addition to the special tracks there will be a third oral session dedicated to late-breaking results on other topics in infectious diseases and clinical microbiology. They include abstracts on the diagnosis of the Zika virus, on late complications of Ebola or on improvements in the diagnosis and treatment of tuberculosis.
Commenting on this year’s selection, Prof. Winfried Kern, ECCMID Programme Director, said: “In view of these two pressing problems of major concern we have opened up two special tracks for late- breaking abstracts on these two topics this year. Refugee and migrant health is a hot topic, as you can imagine. Researchers will present the most recent data on this topic, which will help healthcare providers and policy makers tackle the challenges we are facing in the treatment of migrants in host countries today. The spread of plasmid-borne colistin resistance is also a major concern. The first reports came out in last November and we have now evidence that this plasmid-mediated resistance has spread all over the world with report coming from almost 20 countries. At ECCMID we will present evidence on how to better deal with plasmid-borne colistin resistance.”
ECCMID 2016 will take place from 9 – 12 April 2016 in Amsterdam, Netherlands. The sessions on LBs are scheduled for Saturday, 9 April, and Tuesday, 12 April.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics